Avatrombopag to Prevent Low Platelet Counts Around CAR T-Cell Therapy
Tests avatrombopag in adults with lymphoma or myeloma receiving CAR T-cell therapy.
Plain-language title generated from the registry record
Registry title: Time-limited Treatment With Avatrombopag Pre- and Post-CAR T-cell Therapy to Prevent Post-CAR T-cell Cytopenias
Key facts
- Where
- Charlottesville, United StatesSee the site
- Phase
- Phase 2
Where in United States
- University of VirginiaCharlottesville, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Virginia
- Trial code
- NCT07895017
- Record updated
- 26 October 2026
- Original description
The purpose of this study is to study how avatrombopag (the study drug) may prevent certain side effects in adults with lymphoma and myeloma getting cancer treatment (CAR-T cell therapy). CAR (Chimeric Antigen Receptor) -T cell therapy is a common way to treat lymphoma and myeloma. However, during this kind of cell therapy a patient is at risk of developing lower-than-normal blood cell counts, including:Read full original descriptionShow less
Time-limited Treatment With Avatrombopag Pre- and Post-CAR T-cell Therapy to Prevent Post-CAR T-cell Cytopenias
The purpose of this study is to study how avatrombopag (the study drug) may prevent certain side effects in adults with lymphoma and myeloma getting cancer treatment (CAR-T cell therapy). CAR (Chimeric Antigen Receptor) -T cell therapy is a common way to treat lymphoma and myeloma. However, during this kind of cell therapy a patient is at risk of developing lower-than-normal blood cell counts, including:
* Red Blood Cells - important for many functions such as moving oxygen from the lungs to the body and moving carbon dioxide (CO2) back to the lungs * White Blood Cells - help fight against infection(s) * Platelets - help stop bleeding by forming clots when there is an injury
When a person's platelet counts are lower than normal, this is called "thrombocytopenia". If you have thrombocytopenia, your body has a harder time stopping a bleed when there is an injury to a blood vessel. Thrombocytopenia over time may require additional treatments such as blood transfusions (getting extra platelets).
Avatrombopag is a drug that has been shown to increase platelet numbers in people with other kinds of conditions. This study is trying to find out if taking avatrombopag both before and after CAR-T cell therapy will prevent platelet counts from getting too low.
This is a research study to see if taking avatrombopag (in the form of pills) before, during, and after CAR-T cell therapy will reduce the chance of having thrombocytopenia as a side effect.
This study is for people who are at high risk of thrombocytopenia after CAR T-Cell Therapy.
Inclusion: Provision of signed and dated informed consent form; Stated willingness to comply with all study procedures and availability for the duration of the study; Male or female, aged ≥ 18 years old; ECOG performance status ≤ 2; Planned to receive FDA approved CAR T-cell therapy for large B-cell lymphoma, follicular lymphoma, mantle-cell lymphoma, chronic lymphocytic lymphoma, or multiple myeloma including (but not limited to): idecabtagene vicleucel, lisocabtagene maraleucel, ciltacabtagene autoleucel, tisagenlecleucel, brexucabtagene autoleucel, or axicabtagene ciloleucel; At least one of the following:; Platelet count <200K; High CAR-HEMATOTOX score; Organ Function per the following criteria:; Plt - >20K CrCl - >30 ml/min, (expectation for participants with chronic kidney disease presenting with CrCl <30 but within 15% of baseline) Bilirubin - <3.0 (unless diagnosed with Gilbert's, can be to PI discretion) AST and ALT - ≤ 3 x ULN; Ability to take oral medication and be willing to adhere to the avatrombopag regimen; Agreement to adhere to Lifestyle Considerations throughout study duration.
Exclusion: Treatment with another investigational drug within 3 weeks prior to registration; Known allergic reactions to components of the avatrombopag, specifically subjects with anaphylaxis, bleeding, or other severe adverse reactions related to avatrombopag or its components; Subjects with acute arterial or venous thromboembolism within the past 6 months; Subjects with a history of MDS or AML; Subjects who are at increased risk for thromboembolism, including patients with platelets > 400k/ul, previously known genetic prothrombotic conditions (e.g., Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency or Protein C or S deficiency) and acquired risk factors (e.g., antiphospholipid syndrome); Pregnancy (urine or blood beta-hcg) or lactation.